SA520411188B1 - جسم مضاد مربوط بالفا - ساينوكلين نشط - Google Patents
جسم مضاد مربوط بالفا - ساينوكلين نشط Download PDFInfo
- Publication number
- SA520411188B1 SA520411188B1 SA520411188A SA520411188A SA520411188B1 SA 520411188 B1 SA520411188 B1 SA 520411188B1 SA 520411188 A SA520411188 A SA 520411188A SA 520411188 A SA520411188 A SA 520411188A SA 520411188 B1 SA520411188 B1 SA 520411188B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- synuclein
- antibody
- alpha
- active
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7047—Fibrils-Filaments-Plaque formation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Ophthalmology & Optometry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762540435P | 2017-08-02 | 2017-08-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA520411188B1 true SA520411188B1 (ar) | 2023-01-08 |
Family
ID=65232133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA520411188A SA520411188B1 (ar) | 2017-08-02 | 2020-01-29 | جسم مضاد مربوط بالفا - ساينوكلين نشط |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11098108B2 (https=) |
| EP (1) | EP3661961A4 (https=) |
| JP (1) | JP7204235B2 (https=) |
| KR (1) | KR102826089B1 (https=) |
| CN (1) | CN111225923B (https=) |
| AU (1) | AU2018312441B2 (https=) |
| BR (1) | BR112020001970A2 (https=) |
| IL (1) | IL272361B2 (https=) |
| SA (1) | SA520411188B1 (https=) |
| WO (1) | WO2019023809A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10364286B2 (en) * | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| BR112019013953A2 (pt) | 2017-01-06 | 2020-02-11 | Abl Bio Inc. | Anticorpo anti-a-syn e uso do mesmo |
| CA3051839A1 (en) | 2017-02-17 | 2018-08-23 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
| EP3618870A4 (en) | 2017-05-01 | 2021-04-21 | The Trustees of The University of Pennsylvania | MONOCLONAL ANTIBODIES AGAINST ALPHA-SYNUCLEIN FIBRILLES |
| EP3661961A4 (en) | 2017-08-02 | 2021-04-14 | Stressmarq Biosciences Inc. | ANTIBODIES BINDING TO ACTIVE ALPHA-SYNUCLEIN |
| EP3725806A4 (en) | 2017-12-14 | 2022-03-30 | ABL Bio Inc. | BISPECIFIC ANTIBODIES AGAINST A-SYN/IGF1R AND ASSOCIATED USE |
| EP4268842A3 (en) * | 2019-06-14 | 2024-05-22 | ABL Bio, Inc. | BISPECIFIC ANTIBODY AGAINST a-SYN/IGF1R AND USE THEREOF |
| US20230025707A1 (en) * | 2019-11-19 | 2023-01-26 | The Trustees Of The University Of Pennsylvania | Anti-Alpha-Synuclein Monoclonal Antibodies, and Methods Using Same |
| NL2025332B1 (en) | 2020-04-10 | 2021-10-26 | Syngle Therapeutics B V | Novel alpha-synuclein binding antibodies, or antigen binding portions thereof. |
| KR102505164B1 (ko) * | 2020-09-29 | 2023-02-28 | 서울대학교산학협력단 | 신경퇴행성 질환의 예방 또는 치료용 펩타이드 및 이를 포함하는 약학 조성물 |
| CN113912713B (zh) * | 2021-12-15 | 2022-03-08 | 北京凯祥弘康生物科技有限公司 | 一种抗α-突触核蛋白的单克隆抗体及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3823313A1 (de) | 1988-07-09 | 1990-01-11 | Henkel Kgaa | Fussbodenreinigungsgeraet |
| US20040143093A1 (en) | 2002-07-11 | 2004-07-22 | Ralph Zahn | Method for inducing a conformational transition in proteins, such as pathogenic/infectious proteins, and their use |
| US9034337B2 (en) * | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| PT2282758T (pt) | 2008-04-29 | 2019-02-12 | Bioarctic Ab | Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína |
| WO2009152607A1 (en) * | 2008-06-16 | 2009-12-23 | Ottawa Hospital Research Institute | Methods and kits for diagnosing neurodegenerative disease |
| CN102317316B (zh) | 2008-12-19 | 2014-08-13 | 帕尼玛制药股份公司 | 人抗α突触核蛋白自身抗体 |
| JP5894939B2 (ja) * | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
| CA2818173C (en) | 2010-11-30 | 2022-05-03 | Genentech, Inc. | Low affinity blood brain barrier receptor antibodies and uses therefor |
| CA2840224C (en) | 2011-06-22 | 2019-08-13 | The General Hospital Corporation | Treatment of proteinopathies |
| SI2723379T1 (sl) | 2011-06-23 | 2019-03-29 | Biogen International Neuroscience Gmbh | Molekule, ki se vežejo ma anti alfa-sinuklein |
| DK2807188T3 (da) * | 2012-01-27 | 2019-10-07 | Prothena Biosciences Ltd | Humaniserede antistoffer, der genkender alpha-synuclein |
| EP3594240B1 (en) | 2013-05-20 | 2023-12-06 | F. Hoffmann-La Roche AG | Anti-transferrin receptor antibodies and methods of use |
| LT3071597T (lt) * | 2013-11-21 | 2020-10-12 | F. Hoffmann-La Roche Ag | Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai |
| DK3114141T3 (da) | 2014-03-06 | 2020-08-10 | Nat Res Council Canada | Insulinlignende vækstfaktor 1-receptor-specifikke antistoffer og anvendelse deraf |
| PE20170088A1 (es) | 2014-03-06 | 2017-03-09 | Nat Res Council Canada | Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos |
| NZ724869A (en) | 2014-03-06 | 2022-07-01 | Nat Res Council Canada | Insulin-like growth factor 1 receptor -specific antibodies and uses thereof |
| CN103983778B (zh) * | 2014-05-08 | 2016-04-13 | 首都医科大学宣武医院 | 一种检测受实验者体液体外促进疾病相关蛋白聚合能力的方法 |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| EP3661961A4 (en) | 2017-08-02 | 2021-04-14 | Stressmarq Biosciences Inc. | ANTIBODIES BINDING TO ACTIVE ALPHA-SYNUCLEIN |
-
2018
- 2018-08-02 EP EP18840781.1A patent/EP3661961A4/en active Pending
- 2018-08-02 JP JP2020528498A patent/JP7204235B2/ja active Active
- 2018-08-02 BR BR112020001970-4A patent/BR112020001970A2/pt unknown
- 2018-08-02 CN CN201880051765.4A patent/CN111225923B/zh active Active
- 2018-08-02 AU AU2018312441A patent/AU2018312441B2/en active Active
- 2018-08-02 KR KR1020207003980A patent/KR102826089B1/ko active Active
- 2018-08-02 US US16/635,943 patent/US11098108B2/en active Active
- 2018-08-02 WO PCT/CA2018/050952 patent/WO2019023809A1/en not_active Ceased
- 2018-08-02 IL IL272361A patent/IL272361B2/en unknown
-
2020
- 2020-01-29 SA SA520411188A patent/SA520411188B1/ar unknown
-
2021
- 2021-07-21 US US17/381,661 patent/US11919947B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN111225923A (zh) | 2020-06-02 |
| EP3661961A1 (en) | 2020-06-10 |
| JP7204235B2 (ja) | 2023-01-16 |
| AU2018312441A1 (en) | 2020-02-06 |
| IL272361A (en) | 2020-03-31 |
| KR20200033880A (ko) | 2020-03-30 |
| JP2020529473A (ja) | 2020-10-08 |
| US20210139569A1 (en) | 2021-05-13 |
| US11919947B2 (en) | 2024-03-05 |
| BR112020001970A2 (pt) | 2020-08-04 |
| IL272361B1 (en) | 2025-02-01 |
| WO2019023809A1 (en) | 2019-02-07 |
| EP3661961A4 (en) | 2021-04-14 |
| KR102826089B1 (ko) | 2025-06-30 |
| CN111225923B (zh) | 2024-09-24 |
| US11098108B2 (en) | 2021-08-24 |
| IL272361B2 (en) | 2025-06-01 |
| US20210355202A1 (en) | 2021-11-18 |
| AU2018312441B2 (en) | 2024-10-17 |
| CA3071634A1 (en) | 2019-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA520411188B1 (ar) | جسم مضاد مربوط بالفا - ساينوكلين نشط | |
| EP2495327B1 (en) | Methods and compositions to treat and detect misfolded-SOD1 mediated diseases | |
| US8709422B2 (en) | Methods and compositions to treat and detect misfolded-SOD1 mediated diseases | |
| Ryan et al. | Aβ-directed single-chain antibody delivery via a serotype-1 AAV vector improves learning behavior and pathology in Alzheimer's disease mice | |
| JP2022528459A (ja) | 融合構築物及びその使用 | |
| TWI592423B (zh) | 可辨識致病性ｔｄｐ－４３之抗體及其用途 | |
| DK1989308T3 (en) | Methods and compositions for treating and detecting failed SOD1-mediated diseases | |
| CA3071634C (en) | Antibody binding active alpha-synuclein | |
| HK1175500B (en) | Methods and compositions to treat and detect misfolded-sod1 mediated diseases | |
| HK1175500A (en) | Methods and compositions to treat and detect misfolded-sod1 mediated diseases | |
| HK1124885A (en) | Methods and compositions to treat and detect misfolded-sod1 mediated diseases | |
| HK1124885B (en) | Methods and compositions to treat and detect misfolded-sod1 mediated diseases | |
| HK1176378A (en) | Methods and compositions to treat and detect misfolded-sod1 mediated diseases | |
| HK1175810A (en) | Methods and compositions to treat and detect misfolded-sod1 mediated diseases | |
| HK1175501A (en) | Methods and compositions to treat and detect misfolded-sod1 mediated diseases |